(Axios) – A pair of setbacks to drugs for Alzheimer’s disease and ALS on Friday served as another reminder that widely touted treatments for desperate patients aren’t necessarily a sure thing. Why it matters: Drugs are increasingly judged on the probability they’ll work instead of real-world clinical results — often with energetic lobbying by patient advocacy groups. (Read More)